Abstract
The incidence of maternal-to-fetal human immunodeficiency virus type 1 (HIV-1) transmission is 25-30% in absence of antiretroviral therapy, and is inversely associated with Human leukocyte antigens (HLA) class-I discordance. Based on our earlier report that mixed lymphocyte reactions (MLR) induce a ribonuclease (RNase) that inhibits HIV-1 replication, we proposed that maternal-fetal alloantigen stimulation activates factors that protect the fetus against vertically- transmitted infections. We investigate here whether the degree of mother-infant HLA discordance associates with the ability to produce anti-HIV-1 alloantigen-stimulated factor (ASF), and affects placental RNases. We also determine whether such HLA association is influenced by the mothers HIV-1 status. Paired maternal and cord blood leukocytes were tested for the induction of ASF by MLR, and typed for HLA-A and – B. The placentas were tested for mRNA expression of three RNases. Neonate anti-mother, but not mother anti-neonate MLR generated supernatants with anti-HIV-1 activity, that was associated with HLA class I discordance. This HLA association was not seen in the HIV-infected cohort. HLA class I discordance was also associated with expression of placental RNase 1. Our findings are consistent with the hypothesis that HLA class I discordance induces expression of RNases in the placenta that contribute to innate host resistance to HIV-1 and other viral infections.
Keywords: Anti-HIV-1 activity, RNases, HLA class-I discordance
Current HIV Research
Title: Fetal-Maternal HLA-A and – B Discordance is Associated with Placental RNase Expression and Anti-HIV-1 Activity
Volume: 6 Issue: 4
Author(s): Victoria Ines Bedoya, Fabian Alberto Jaimes, Julio C. Delgado, Claudia Rugeles, Xiomara Usuga, Wildeman Zapata, Maria Eugenia Castano, Adriano Boasso, Gene Shearer and Maria Teresa Rugeles
Affiliation:
Keywords: Anti-HIV-1 activity, RNases, HLA class-I discordance
Abstract: The incidence of maternal-to-fetal human immunodeficiency virus type 1 (HIV-1) transmission is 25-30% in absence of antiretroviral therapy, and is inversely associated with Human leukocyte antigens (HLA) class-I discordance. Based on our earlier report that mixed lymphocyte reactions (MLR) induce a ribonuclease (RNase) that inhibits HIV-1 replication, we proposed that maternal-fetal alloantigen stimulation activates factors that protect the fetus against vertically- transmitted infections. We investigate here whether the degree of mother-infant HLA discordance associates with the ability to produce anti-HIV-1 alloantigen-stimulated factor (ASF), and affects placental RNases. We also determine whether such HLA association is influenced by the mothers HIV-1 status. Paired maternal and cord blood leukocytes were tested for the induction of ASF by MLR, and typed for HLA-A and – B. The placentas were tested for mRNA expression of three RNases. Neonate anti-mother, but not mother anti-neonate MLR generated supernatants with anti-HIV-1 activity, that was associated with HLA class I discordance. This HLA association was not seen in the HIV-infected cohort. HLA class I discordance was also associated with expression of placental RNase 1. Our findings are consistent with the hypothesis that HLA class I discordance induces expression of RNases in the placenta that contribute to innate host resistance to HIV-1 and other viral infections.
Export Options
About this article
Cite this article as:
Bedoya Ines Victoria, Jaimes Alberto Fabian, Delgado C. Julio, Rugeles Claudia, Usuga Xiomara, Zapata Wildeman, Castano Eugenia Maria, Boasso Adriano, Shearer Gene and Rugeles Teresa Maria, Fetal-Maternal HLA-A and – B Discordance is Associated with Placental RNase Expression and Anti-HIV-1 Activity, Current HIV Research 2008; 6 (4) . https://dx.doi.org/10.2174/157016208785132536
DOI https://dx.doi.org/10.2174/157016208785132536 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Current Pharmaceutical Design Is Effective and Safe a Radiochemotherapy Approach in Elderly Cancer Patients? A Review
Anti-Cancer Agents in Medicinal Chemistry Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers
Current Medicinal Chemistry When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Current Signal Transduction Therapy Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice
Current Cancer Drug Targets New Cancer Chemotherapy Agents: Inhibitors of DNA Polymerase
Current Drug Therapy The Effect of Alcohol on Gastrointestinal Motility
Reviews on Recent Clinical Trials DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Cell Responses to Oxidative Stressors
Current Pharmaceutical Design Molecular Architecture of Tumor Suppressor p53
Current Topics in Medicinal Chemistry Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
Current Gene Therapy Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy NSAIDs and Chemoprevention
Current Cancer Drug Targets